Biologics Safety Testing Market by Product (Kits, Reagents, Instruments), Services, Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden), Product & Services by Application (Vaccines, mAbs, CGT), End User, Competition, Region - Global Forecast to 2031
The global biologics safety testing market is estimated to reach USD 9.66 billion by 2031 from USD 5.57 billion in 2026, at a CAGR of 11.6% during the forecast period of 2026 to 2031. The global biologics safety testing market is projected to witness strong growth over the forecast period, supported by the rising biologics and biosimilars pipeline and the growth of advanced modalities such as cell & gene therapies and mRNA products. Market estimates from published industry sources indicate robust growth through 2031, driven by strong expansion in biologics development and manufacturing, as well as rising demand for stringent safety testing to ensure product quality. However, the high cost of advanced testing equipment, limited specialized expertise, and regulatory divergence across regions are expected to remain key factors restraining broader market expansion.
“The assays, kits, and reagents segment accounted for the largest share by product in the biologics safety testing market in 2025.”
Based on product, the biologics safety testing market is broadly segmented into assays, kits & reagents, and instruments. In 2025, assays, kits, and reagents accounted for the largest share of the biologics safety testing market, driven by their widespread use in routine applications such as endotoxin, mycoplasma, sterility, and viral detection testing. Their ease of use, reliability, and compatibility with automated and high-throughput systems make them essential across laboratories. Additionally, their cost-effectiveness and ability to deliver rapid, reproducible results support consistent demand from biopharmaceutical companies, CROs, and research institutions globally.
“The monoclonal antibodies and therapeutic proteins segment accounted for the largest share of the biologics safety testing product applications market in 2025.”
Based on application, the global biologics safety testing product market is segmented into vaccines, monoclonal antibodies & therapeutic proteins, cellular & gene therapy products, blood & blood products, and other applications. The monoclonal antibodies & therapeutic proteins segment accounted for the largest share of the biologics safety testing product market in 2025, driven by their extensive use in treating chronic and complex diseases. The growing pipeline, increasing approvals, and large-scale commercial production of these biologics require rigorous safety testing. Additionally, stringent regulatory requirements and the need to ensure product purity, potency, and consistency further contribute to the segment’s market position globally.
“The Asia Pacific is growing at the highest CAGR in the biologics safety testing market from 2026 to 2031.”
The biologics safety testing market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is estimated to grow at the highest CAGR, supported by expanding biopharmaceutical manufacturing, increasing adoption of biologics and biosimilars, and rising clinical trial activity. Growth is further driven by improving regulatory frameworks, and the presence of key regional and global players such as Samsung Biologics and WuXi AppTec is actively strengthening biologics development and safety testing capabilities.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the biologics safety testing market by offering, by test type, by application (product & service applications), by end user (product & service end users), and by region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the biologics safety testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the biologics safety testing market. This report covers competitive analysis of top players and upcoming startups in the biologics safety testing market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall biologics safety testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
“The assays, kits, and reagents segment accounted for the largest share by product in the biologics safety testing market in 2025.”
Based on product, the biologics safety testing market is broadly segmented into assays, kits & reagents, and instruments. In 2025, assays, kits, and reagents accounted for the largest share of the biologics safety testing market, driven by their widespread use in routine applications such as endotoxin, mycoplasma, sterility, and viral detection testing. Their ease of use, reliability, and compatibility with automated and high-throughput systems make them essential across laboratories. Additionally, their cost-effectiveness and ability to deliver rapid, reproducible results support consistent demand from biopharmaceutical companies, CROs, and research institutions globally.
“The monoclonal antibodies and therapeutic proteins segment accounted for the largest share of the biologics safety testing product applications market in 2025.”
Based on application, the global biologics safety testing product market is segmented into vaccines, monoclonal antibodies & therapeutic proteins, cellular & gene therapy products, blood & blood products, and other applications. The monoclonal antibodies & therapeutic proteins segment accounted for the largest share of the biologics safety testing product market in 2025, driven by their extensive use in treating chronic and complex diseases. The growing pipeline, increasing approvals, and large-scale commercial production of these biologics require rigorous safety testing. Additionally, stringent regulatory requirements and the need to ensure product purity, potency, and consistency further contribute to the segment’s market position globally.
“The Asia Pacific is growing at the highest CAGR in the biologics safety testing market from 2026 to 2031.”
The biologics safety testing market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is estimated to grow at the highest CAGR, supported by expanding biopharmaceutical manufacturing, increasing adoption of biologics and biosimilars, and rising clinical trial activity. Growth is further driven by improving regulatory frameworks, and the presence of key regional and global players such as Samsung Biologics and WuXi AppTec is actively strengthening biologics development and safety testing capabilities.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side - 30%
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Lonza
- FUJIFILM Corporation
- Sartorius AG
- F. Hoffmann- La Roche Ltd.
- Charles River Laboratories
- bioM?rieux
- WuXi AppTec
- SGS Soci?t? G?n?rale de Surveillance SA
- Sotera Health
- Samsung Biologics
- GenScript
- Agilent Technologies, Inc.
- Syngene International Limited
- Eurofins Scientific
- Laboratory Corporation of America Holdings
- Bio-Rad Laboratories, Inc.
- QIAGEN
This research report categorizes the biologics safety testing market by offering, by test type, by application (product & service applications), by end user (product & service end users), and by region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the biologics safety testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the biologics safety testing market. This report covers competitive analysis of top players and upcoming startups in the biologics safety testing market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall biologics safety testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising biologics and biosimilars pipeline, stringent and evolving regulatory requirements, growth of advanced modalities like cell & gene therapies and mRNA products, expansion of CDMOs and the structural shift toward outsourced testing), restraints (high cost of advanced testing equipment and limited specialized expertise, regulatory divergence across regions), opportunities (growing focus on next-generation therapeutics, the shift toward animal-free testing approaches) and challenges (assay standardization gap) influencing the growth of biologics safety testing market
- Product Development/Innovation: Detailed insights on newly launched products of the biologics safety testing market
- Market Development: Comprehensive information about lucrative markets – the report analyses the biologics safety testing market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biologics safety testing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation (Japan), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Charles River Laboratories (US), among others
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW
3.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING & REGION
3.3 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising biologics and biosimilars pipeline
4.2.1.2 Stringent and evolving regulatory requirements
4.2.1.3 Growth of advanced modalities like cell & gene therapies and mRNA products
4.2.1.4 Rising demand for outsourced development/manufacturing and testing
4.2.2 RESTRAINTS
4.2.2.1 High cost of advanced testing equipment and limited specialized expertise
4.2.2.2 Regulatory divergence across regions
4.2.3 OPPORTUNITIES
4.2.3.1 Growing focus on next-generation therapeutics
4.2.3.2 Shift toward animal-free testing approaches
4.2.4 CHALLENGES
4.2.4.1 Assay standardization gap
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL BIOLOGICS SAFETY TESTING MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025
5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025
5.6 KEY CONFERENCES & EVENTS
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT/FUNDING ACTIVITY
5.9 IMPACT OF US TARIFFS—BIOLOGICS SAFETY TESTING MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRIES/REGIONS
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
5.9.5 IMPACT ON END-USE INDUSTRIES
5.9.5.1 Pharmaceutical and biotechnology companies
5.9.5.2 CROs & CDMOs
5.9.5.3 Academic & Research Institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY TECHNOLOGIES
6.1.1 POLYMERASE CHAIN REACTION (PCR)
6.1.2 NEXT-GENERATION SEQUENCING (NGS)
6.2 ADJACENT TECHNOLOGIES
6.2.1 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
6.3 COMPLEMENTARY TECHNOLOGIES
6.3.1 LAB-ON-A-CHIP (LOC) SYSTEMS
6.3.2 HIGH-CONTENT SCREENING (HCS)
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015–2025
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET
6.7.1 TOP USE CASES AND MARKET POTENTIAL
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
9 BIOLOGICS SAFETY TESTING MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 SERVICES
9.2.1 VIRUS SAFETY TESTING SERVICES
9.2.1.1 Rising focus on development of advanced therapies to drive growth
9.2.2 STERILITY TESTING SERVICES
9.2.2.1 Need for sterility testing at each stage of drug development to propel growth
9.2.3 MYCOPLASMA TESTING SERVICES
9.2.3.1 Increasing focus on development of biologics and biosimilars to promote growth
9.2.4 ENDOTOXIN TESTING SERVICES
9.2.4.1 Stringent regulatory requirements to drive market
9.2.5 BIOBURDEN TESTING SERVICES
9.2.5.1 Rising adoption of advanced testing solutions for contamination risk mitigation to propel the growth
9.2.6 OTHER BST SERVICES
9.3 PRODUCTS
9.3.1 ASSAYS, KITS, AND REAGENTS
9.3.1.1 Detection kits
9.3.1.1.1 Expanding advanced biologics pipelines and faster QC workflows are lifting demand for high-sensitivity detection kits
9.3.1.2 Endotoxin testing reagents
9.3.1.2.1 Regulatory acceptance of recombinant methods and shift to simpler, animal-free QC workflows are accelerating demand for endotoxin testing reagents
9.3.1.3 Sterility testing media & kits
9.3.1.3.1 Rapid release needs and shift toward standardized aseptic QC strengthen demand for sterility testing media and kits
9.3.1.4 Bioburden enumeration
9.3.1.4.1 Stricter contamination control expectations and faster microbiology workflows drive demand for bioburden enumeration solutions
9.3.1.5 Other BST assays, kits, and reagents
9.3.2 INSTRUMENTS
9.3.2.1 Detection & imaging systems
9.3.2.1.1 Rapid molecular testing, automated microbiology, and standardized QC workflows are increasing the demand
9.3.2.2 Sequencing instruments
9.3.2.2.1 Wider adoption of NGS-based viral safety workflows and smaller, more accessible platforms support demand
9.3.2.3 Automated sterility testing systems
9.3.2.3.1 Shorter release timelines and wider adoption of rapid microbiology to drive growth
9.3.2.4 Other BST instruments
10 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE
10.1 INTRODUCTION
10.2 VIRUS SAFETY TESTS
10.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
10.3 STERILITY TESTS
10.3.1 MANDATORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO PROMOTE SEGMENT GROWTH
10.4 ENDOTOXIN TESTS
10.4.1 GROWING R&D ACTIVITIES FOR DEVELOPMENT OF BIOLOGICS TO PROMOTE THE GROWTH OF THE SEGMENT
10.5 MYCOPLASMA TESTS
10.5.1 RISING CONCERN FOR CELL CULTURE CONTAMINATION TO DRIVE THE SEGMENT GROWTH
10.6 BIOBURDEN TESTS
10.6.1 GROWING CONCERNS FOR DRUG SAFETY STANDARDS HAVE INCREASED THE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING IN THE BIOLOGICS INDUSTRY
10.7 RESIDUAL HCP & DNA DETECTION TESTS
10.7.1 STRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO CONTRIBUTE TO THE SEGMENT GROWTH
10.8 OTHER TESTS
11 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS
11.2.1 GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO CONTRIBUTE TO THE MARKET SHARE
11.3 VACCINES
11.3.1 EXPANDING VACCINE PLATFORM COMPLEXITY AND STRICTER GLOBAL QUALITY EXPECTATIONS TO DRIVE MARKET GROWTH
11.4 CELLULAR & GENE THERAPY PRODUCTS
11.4.1 GROWING PRODUCT MANUFACTURING COMPLEXITY IS ACCELERATING DEMAND
11.5 BLOOD & BLOOD PRODUCTS
11.5.1 GROWING DEMAND FOR BLOOD PRODUCTS TO PROMOTE MARKET GROWTH
11.6 OTHER APPLICATIONS
12 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING
12.2.1 EXPANDING ANTIBODY PIPELINES AND RISING BIOSIMILAR MANUFACTURING ARE DRIVING GROWTH
12.3 VACCINE SAFETY TESTING
12.3.1 EXPANSION OF VACCINE SAFETY TESTING DRIVEN BY ADVANCED PLATFORMS AND REGULATORY STRINGENCY
12.4 CELLULAR & GENE THERAPY SAFETY TESTING
12.4.1 EXPANDING ADVANCED THERAPY MANUFACTURING AND TIGHTER STERILITY REQUIREMENTS TO ACCELERATE DEMAND
12.5 BLOOD & BLOOD PRODUCT SAFETY TESTING
12.5.1 PLASMA PRODUCT SAFETY REQUIREMENTS AND NEW ASSAY APPROVALS TO DRIVE MARKET GROWTH
12.6 OTHER APPLICATIONS
13 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 RISING ADOPTION OF SAFETY TESTING PRODUCTS BY BIOPHARMA MANUFACTURERS
13.3 CROS & CDMOS
13.3.1 RISING OUTSOURCING OF BIOLOGICS DEVELOPMENT AND MANUFACTURING ACCELERATES MARKET GROWTH
13.4 ACADEMIC & RESEARCH INSTITUTES
13.4.1 EXPANDING TRANSLATIONAL BIOLOGICS RESEARCH AND EARLY-STAGE PLATFORM DEVELOPMENT DRIVES MARKET GROWTH
13.5 OTHER END USERS
14 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER
14.1 INTRODUCTION
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.2.1 GROWING OUTSOURCING OF SAFETY TESTING SERVICES BY BIOPHARMA COMPANIES TO AID GROWTH
14.3 ACADEMIC & RESEARCH INSTITUTES
14.3.1 RISING TRANSLATIONAL RESEARCH IS DRIVING ADOPTION OF BIOLOGICS SAFETY TESTING SERVICES IN ACADEMIC INSTITUTES
14.4 OTHER END USERS
15 BIOLOGICS SAFETY TESTING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 US
15.2.1.1 Leading biopharma industry, federal funding, mature ecosystem, and biologics development activity to propel market growth
15.2.2 CANADA
15.2.2.1 Investments for expanding biomanufacturing capacity to propel market growth
15.3 EUROPE
15.3.1 GERMANY
15.3.1.1 Expansion initiatives by key market players to support market growth
15.3.2 UK
15.3.2.1 Emphasis on vaccine manufacturing and biotech R&D to drive market
15.3.3 FRANCE
15.3.3.1 Strong government funding driving biologics innovation and testing demand
15.3.4 ITALY
15.3.4.1 Manufacturing investment and strong R&D intensity support market growth
15.3.5 SPAIN
15.3.5.1 Growing expansion of biotech companies and increasing R&D expenditure to drive market
15.3.6 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 CHINA
15.4.1.1 Rising biologics development driving market growth
15.4.2 JAPAN
15.4.2.1 Government initiatives and expansion of biopharma companies to boost market
15.4.3 INDIA
15.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies drive market growth
15.4.4 SOUTH KOREA
15.4.4.1 Growing focus on advancing bioprocessing sector to drive market
15.4.5 AUSTRALIA
15.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth
15.4.6 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 BRAZIL
15.5.1.1 Expanding biologics manufacturing investment and rising clinical development activity are driving market growth
15.5.2 MEXICO
15.5.2.1 Increasing government support for biopharmaceutical production to drive market
15.5.3 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 GCC COUNTRIES
15.6.1.1 Saudi Arabia
15.6.1.1.1 Increasing healthcare expenditure and rising focus of key players on expansion to support growth
15.6.1.2 United Arab Emirates
15.6.1.2.1 Developing biopharma sector to drive market
15.6.1.3 Rest of GCC countries
15.6.2 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 RISING AWARENESS AND COLLABORATIVE INITIATIVES TO DRIVE ADOPTION
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
16.3 REVENUE ANALYSIS
16.4 MARKET SHARE ANALYSIS
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Offering footprint
16.5.5.4 Test type footprint
16.5.5.5 Application footprint of companies
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Competitive benchmarking of key startups/SMEs
16.7 COMPANY VALUATION & FINANCIAL METRICS
16.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES
16.9.2 DEALS
16.9.3 EXPANSIONS
17 COMPANY PROFILES
17.1 MAJOR PALYER
17.1.1 THERMO FISHER SCIENTIFIC INC.
17.1.1.1 Business overview
17.1.1.2 Products/Services/Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Service launches
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses and competitive threats
17.1.2 CHARLES RIVER LABORATORIES
17.1.2.1 Business overview
17.1.2.2 Products/Services/Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Product and service launches
17.1.2.3.2 Deals
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses and competitive threats
17.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
17.1.3.1 Business overview
17.1.3.2 Products/Services/Solutions offered
17.1.3.3 Recent developments
17.1.3.3.1 Deals
17.1.3.3.2 Expansions
17.1.3.4 MnM view
17.1.3.4.1 Key strengths
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses and competitive threats
17.1.4 F. HOFFMANN-LA ROCHE LTD.
17.1.4.1 Business overview
17.1.4.2 Products/Services/Solutions offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches
17.1.4.3.2 Expansions
17.1.4.4 MnM view
17.1.4.4.1 Key strengths
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses and competitive threats
17.1.5 MERCK KGAA
17.1.5.1 Business overview
17.1.5.2 Products/Services/Solutions offered
17.1.5.3 Recent developments
17.1.5.3.1 Expansions
17.1.5.4 MnM view
17.1.5.4.1 Key strengths
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weaknesses and competitive threats
17.1.6 SARTORIUS AG
17.1.6.1 Business overview
17.1.6.2 Products/Services/Solutions offered
17.1.6.3 Recent developments
17.1.6.3.1 Product launches
17.1.7 LONZA
17.1.7.1 Business overview
17.1.7.2 Products/Services/Solutions offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches
17.1.7.3.2 Deals
17.1.8 FUJIFILM CORPORATION
17.1.8.1 Business overview
17.1.8.2 Products/Services/Solutions offered
17.1.8.3 Recent developments
17.1.8.3.1 Expansions
17.1.9 BIOM?RIEUX
17.1.9.1 Business overview
17.1.9.2 Products/Services/Solutions offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches
17.1.9.3.2 Deals
17.1.10 MARAVAI LIFESCIENCES
17.1.10.1 Business overview
17.1.10.2 Products/Services/Solutions offered
17.1.10.3 Recent developments
17.1.10.3.1 Deals
17.1.11 WUXI APPTEC
17.1.11.1 Business overview
17.1.11.2 Products/Services/Solutions offered
17.1.12 SGS SOCI?T? G?N?RALE DE SURVEILLANCE SA
17.1.12.1 Business overview
17.1.12.2 Products/Services/Solutions offered
17.1.12.3 Recent developments
17.1.12.3.1 Service launches
17.1.12.3.2 Expansions
17.1.13 SOTERA HEALTH
17.1.13.1 Business overview
17.1.13.2 Products/Services/Solutions offered
17.1.13.3 Recent developments
17.1.13.3.1 Service launches
17.1.13.3.2 Expansions
17.1.14 SAMSUNG BIOLOGICS
17.1.14.1 Business overview
17.1.14.2 Products/Services/Solutions offered
17.1.14.3 Recent developments
17.1.14.3.1 Deals
17.1.14.3.2 Expansions
17.1.15 GENSCRIPT
17.1.15.1 Business overview
17.1.15.2 Products/Services/Solutions offered
17.1.16 AGILENT TECHNOLOGIES, INC.
17.1.16.1 Business overview
17.1.16.2 Products/Services/Solutions offered
17.1.17 SYNGENE INTERNATIONAL LIMITED
17.1.17.1 Business overview
17.1.17.2 Products/Services/Solutions offered
17.1.18 EUROFINS SCIENTIFIC
17.1.18.1 Business overview
17.1.18.2 Products/Services/Solutions offered
17.1.18.3 Recent developments
17.1.18.3.1 Service launches
17.1.18.3.2 Expansions
17.1.19 BIO-RAD LABORATORIES, INC.
17.1.19.1 Business overview
17.1.19.2 Products/Services/Solutions offered
17.1.19.3 Recent developments
17.1.19.3.1 Product launches
17.1.19.3.2 Deals
17.1.20 QIAGEN
17.1.20.1 Business overview
17.1.20.2 Products/Services/Solutions offered
17.1.20.3 Recent developments
17.1.20.3.1 Product launches
17.2 OTHER PLAYERS
17.2.1 PROMEGA CORPORATION
17.2.2 CATALENT, INC.
17.2.3 ASSOCIATES OF CAPE COD, INC.
17.2.4 CLEAN BIOLOGICS
17.2.5 PATHOQUEST
17.2.6 PACIFIC BIOLABS
17.2.7 ARL BIO PHARMA, INC.
17.2.8 FRONTAGE LABS
17.2.9 CREATIVE BIOGENE
17.2.10 ADVAXIA BIOLOGICS
18 RESEARCH METHODOLOGY
18.1 RESEARCH DATA
18.1.1 SECONDARY DATA
18.1.2 PRIMARY DATA
18.2 MARKET ESTIMATION METHODOLOGY
18.2.1 MARKET SIZE ESTIMATION
18.2.2 INSIGHTS OF PRIMARY EXPERTS
18.2.3 TOP-DOWN APPROACH
18.3 MARKET GROWTH RATE PROJECTIONS
18.4 MARKET BREAKDOWN AND DATA TRIANGULATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.7 RISK ANALYSIS
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS
19.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW
3.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING & REGION
3.3 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising biologics and biosimilars pipeline
4.2.1.2 Stringent and evolving regulatory requirements
4.2.1.3 Growth of advanced modalities like cell & gene therapies and mRNA products
4.2.1.4 Rising demand for outsourced development/manufacturing and testing
4.2.2 RESTRAINTS
4.2.2.1 High cost of advanced testing equipment and limited specialized expertise
4.2.2.2 Regulatory divergence across regions
4.2.3 OPPORTUNITIES
4.2.3.1 Growing focus on next-generation therapeutics
4.2.3.2 Shift toward animal-free testing approaches
4.2.4 CHALLENGES
4.2.4.1 Assay standardization gap
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL BIOLOGICS SAFETY TESTING MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025
5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025
5.6 KEY CONFERENCES & EVENTS
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT/FUNDING ACTIVITY
5.9 IMPACT OF US TARIFFS—BIOLOGICS SAFETY TESTING MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRIES/REGIONS
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
5.9.5 IMPACT ON END-USE INDUSTRIES
5.9.5.1 Pharmaceutical and biotechnology companies
5.9.5.2 CROs & CDMOs
5.9.5.3 Academic & Research Institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY TECHNOLOGIES
6.1.1 POLYMERASE CHAIN REACTION (PCR)
6.1.2 NEXT-GENERATION SEQUENCING (NGS)
6.2 ADJACENT TECHNOLOGIES
6.2.1 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
6.3 COMPLEMENTARY TECHNOLOGIES
6.3.1 LAB-ON-A-CHIP (LOC) SYSTEMS
6.3.2 HIGH-CONTENT SCREENING (HCS)
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015–2025
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET
6.7.1 TOP USE CASES AND MARKET POTENTIAL
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
9 BIOLOGICS SAFETY TESTING MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 SERVICES
9.2.1 VIRUS SAFETY TESTING SERVICES
9.2.1.1 Rising focus on development of advanced therapies to drive growth
9.2.2 STERILITY TESTING SERVICES
9.2.2.1 Need for sterility testing at each stage of drug development to propel growth
9.2.3 MYCOPLASMA TESTING SERVICES
9.2.3.1 Increasing focus on development of biologics and biosimilars to promote growth
9.2.4 ENDOTOXIN TESTING SERVICES
9.2.4.1 Stringent regulatory requirements to drive market
9.2.5 BIOBURDEN TESTING SERVICES
9.2.5.1 Rising adoption of advanced testing solutions for contamination risk mitigation to propel the growth
9.2.6 OTHER BST SERVICES
9.3 PRODUCTS
9.3.1 ASSAYS, KITS, AND REAGENTS
9.3.1.1 Detection kits
9.3.1.1.1 Expanding advanced biologics pipelines and faster QC workflows are lifting demand for high-sensitivity detection kits
9.3.1.2 Endotoxin testing reagents
9.3.1.2.1 Regulatory acceptance of recombinant methods and shift to simpler, animal-free QC workflows are accelerating demand for endotoxin testing reagents
9.3.1.3 Sterility testing media & kits
9.3.1.3.1 Rapid release needs and shift toward standardized aseptic QC strengthen demand for sterility testing media and kits
9.3.1.4 Bioburden enumeration
9.3.1.4.1 Stricter contamination control expectations and faster microbiology workflows drive demand for bioburden enumeration solutions
9.3.1.5 Other BST assays, kits, and reagents
9.3.2 INSTRUMENTS
9.3.2.1 Detection & imaging systems
9.3.2.1.1 Rapid molecular testing, automated microbiology, and standardized QC workflows are increasing the demand
9.3.2.2 Sequencing instruments
9.3.2.2.1 Wider adoption of NGS-based viral safety workflows and smaller, more accessible platforms support demand
9.3.2.3 Automated sterility testing systems
9.3.2.3.1 Shorter release timelines and wider adoption of rapid microbiology to drive growth
9.3.2.4 Other BST instruments
10 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE
10.1 INTRODUCTION
10.2 VIRUS SAFETY TESTS
10.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
10.3 STERILITY TESTS
10.3.1 MANDATORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO PROMOTE SEGMENT GROWTH
10.4 ENDOTOXIN TESTS
10.4.1 GROWING R&D ACTIVITIES FOR DEVELOPMENT OF BIOLOGICS TO PROMOTE THE GROWTH OF THE SEGMENT
10.5 MYCOPLASMA TESTS
10.5.1 RISING CONCERN FOR CELL CULTURE CONTAMINATION TO DRIVE THE SEGMENT GROWTH
10.6 BIOBURDEN TESTS
10.6.1 GROWING CONCERNS FOR DRUG SAFETY STANDARDS HAVE INCREASED THE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING IN THE BIOLOGICS INDUSTRY
10.7 RESIDUAL HCP & DNA DETECTION TESTS
10.7.1 STRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO CONTRIBUTE TO THE SEGMENT GROWTH
10.8 OTHER TESTS
11 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS
11.2.1 GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO CONTRIBUTE TO THE MARKET SHARE
11.3 VACCINES
11.3.1 EXPANDING VACCINE PLATFORM COMPLEXITY AND STRICTER GLOBAL QUALITY EXPECTATIONS TO DRIVE MARKET GROWTH
11.4 CELLULAR & GENE THERAPY PRODUCTS
11.4.1 GROWING PRODUCT MANUFACTURING COMPLEXITY IS ACCELERATING DEMAND
11.5 BLOOD & BLOOD PRODUCTS
11.5.1 GROWING DEMAND FOR BLOOD PRODUCTS TO PROMOTE MARKET GROWTH
11.6 OTHER APPLICATIONS
12 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING
12.2.1 EXPANDING ANTIBODY PIPELINES AND RISING BIOSIMILAR MANUFACTURING ARE DRIVING GROWTH
12.3 VACCINE SAFETY TESTING
12.3.1 EXPANSION OF VACCINE SAFETY TESTING DRIVEN BY ADVANCED PLATFORMS AND REGULATORY STRINGENCY
12.4 CELLULAR & GENE THERAPY SAFETY TESTING
12.4.1 EXPANDING ADVANCED THERAPY MANUFACTURING AND TIGHTER STERILITY REQUIREMENTS TO ACCELERATE DEMAND
12.5 BLOOD & BLOOD PRODUCT SAFETY TESTING
12.5.1 PLASMA PRODUCT SAFETY REQUIREMENTS AND NEW ASSAY APPROVALS TO DRIVE MARKET GROWTH
12.6 OTHER APPLICATIONS
13 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 RISING ADOPTION OF SAFETY TESTING PRODUCTS BY BIOPHARMA MANUFACTURERS
13.3 CROS & CDMOS
13.3.1 RISING OUTSOURCING OF BIOLOGICS DEVELOPMENT AND MANUFACTURING ACCELERATES MARKET GROWTH
13.4 ACADEMIC & RESEARCH INSTITUTES
13.4.1 EXPANDING TRANSLATIONAL BIOLOGICS RESEARCH AND EARLY-STAGE PLATFORM DEVELOPMENT DRIVES MARKET GROWTH
13.5 OTHER END USERS
14 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER
14.1 INTRODUCTION
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.2.1 GROWING OUTSOURCING OF SAFETY TESTING SERVICES BY BIOPHARMA COMPANIES TO AID GROWTH
14.3 ACADEMIC & RESEARCH INSTITUTES
14.3.1 RISING TRANSLATIONAL RESEARCH IS DRIVING ADOPTION OF BIOLOGICS SAFETY TESTING SERVICES IN ACADEMIC INSTITUTES
14.4 OTHER END USERS
15 BIOLOGICS SAFETY TESTING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 US
15.2.1.1 Leading biopharma industry, federal funding, mature ecosystem, and biologics development activity to propel market growth
15.2.2 CANADA
15.2.2.1 Investments for expanding biomanufacturing capacity to propel market growth
15.3 EUROPE
15.3.1 GERMANY
15.3.1.1 Expansion initiatives by key market players to support market growth
15.3.2 UK
15.3.2.1 Emphasis on vaccine manufacturing and biotech R&D to drive market
15.3.3 FRANCE
15.3.3.1 Strong government funding driving biologics innovation and testing demand
15.3.4 ITALY
15.3.4.1 Manufacturing investment and strong R&D intensity support market growth
15.3.5 SPAIN
15.3.5.1 Growing expansion of biotech companies and increasing R&D expenditure to drive market
15.3.6 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 CHINA
15.4.1.1 Rising biologics development driving market growth
15.4.2 JAPAN
15.4.2.1 Government initiatives and expansion of biopharma companies to boost market
15.4.3 INDIA
15.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies drive market growth
15.4.4 SOUTH KOREA
15.4.4.1 Growing focus on advancing bioprocessing sector to drive market
15.4.5 AUSTRALIA
15.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth
15.4.6 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 BRAZIL
15.5.1.1 Expanding biologics manufacturing investment and rising clinical development activity are driving market growth
15.5.2 MEXICO
15.5.2.1 Increasing government support for biopharmaceutical production to drive market
15.5.3 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 GCC COUNTRIES
15.6.1.1 Saudi Arabia
15.6.1.1.1 Increasing healthcare expenditure and rising focus of key players on expansion to support growth
15.6.1.2 United Arab Emirates
15.6.1.2.1 Developing biopharma sector to drive market
15.6.1.3 Rest of GCC countries
15.6.2 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 RISING AWARENESS AND COLLABORATIVE INITIATIVES TO DRIVE ADOPTION
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
16.3 REVENUE ANALYSIS
16.4 MARKET SHARE ANALYSIS
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Offering footprint
16.5.5.4 Test type footprint
16.5.5.5 Application footprint of companies
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Competitive benchmarking of key startups/SMEs
16.7 COMPANY VALUATION & FINANCIAL METRICS
16.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES
16.9.2 DEALS
16.9.3 EXPANSIONS
17 COMPANY PROFILES
17.1 MAJOR PALYER
17.1.1 THERMO FISHER SCIENTIFIC INC.
17.1.1.1 Business overview
17.1.1.2 Products/Services/Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Service launches
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses and competitive threats
17.1.2 CHARLES RIVER LABORATORIES
17.1.2.1 Business overview
17.1.2.2 Products/Services/Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Product and service launches
17.1.2.3.2 Deals
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses and competitive threats
17.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
17.1.3.1 Business overview
17.1.3.2 Products/Services/Solutions offered
17.1.3.3 Recent developments
17.1.3.3.1 Deals
17.1.3.3.2 Expansions
17.1.3.4 MnM view
17.1.3.4.1 Key strengths
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses and competitive threats
17.1.4 F. HOFFMANN-LA ROCHE LTD.
17.1.4.1 Business overview
17.1.4.2 Products/Services/Solutions offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches
17.1.4.3.2 Expansions
17.1.4.4 MnM view
17.1.4.4.1 Key strengths
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses and competitive threats
17.1.5 MERCK KGAA
17.1.5.1 Business overview
17.1.5.2 Products/Services/Solutions offered
17.1.5.3 Recent developments
17.1.5.3.1 Expansions
17.1.5.4 MnM view
17.1.5.4.1 Key strengths
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weaknesses and competitive threats
17.1.6 SARTORIUS AG
17.1.6.1 Business overview
17.1.6.2 Products/Services/Solutions offered
17.1.6.3 Recent developments
17.1.6.3.1 Product launches
17.1.7 LONZA
17.1.7.1 Business overview
17.1.7.2 Products/Services/Solutions offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches
17.1.7.3.2 Deals
17.1.8 FUJIFILM CORPORATION
17.1.8.1 Business overview
17.1.8.2 Products/Services/Solutions offered
17.1.8.3 Recent developments
17.1.8.3.1 Expansions
17.1.9 BIOM?RIEUX
17.1.9.1 Business overview
17.1.9.2 Products/Services/Solutions offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches
17.1.9.3.2 Deals
17.1.10 MARAVAI LIFESCIENCES
17.1.10.1 Business overview
17.1.10.2 Products/Services/Solutions offered
17.1.10.3 Recent developments
17.1.10.3.1 Deals
17.1.11 WUXI APPTEC
17.1.11.1 Business overview
17.1.11.2 Products/Services/Solutions offered
17.1.12 SGS SOCI?T? G?N?RALE DE SURVEILLANCE SA
17.1.12.1 Business overview
17.1.12.2 Products/Services/Solutions offered
17.1.12.3 Recent developments
17.1.12.3.1 Service launches
17.1.12.3.2 Expansions
17.1.13 SOTERA HEALTH
17.1.13.1 Business overview
17.1.13.2 Products/Services/Solutions offered
17.1.13.3 Recent developments
17.1.13.3.1 Service launches
17.1.13.3.2 Expansions
17.1.14 SAMSUNG BIOLOGICS
17.1.14.1 Business overview
17.1.14.2 Products/Services/Solutions offered
17.1.14.3 Recent developments
17.1.14.3.1 Deals
17.1.14.3.2 Expansions
17.1.15 GENSCRIPT
17.1.15.1 Business overview
17.1.15.2 Products/Services/Solutions offered
17.1.16 AGILENT TECHNOLOGIES, INC.
17.1.16.1 Business overview
17.1.16.2 Products/Services/Solutions offered
17.1.17 SYNGENE INTERNATIONAL LIMITED
17.1.17.1 Business overview
17.1.17.2 Products/Services/Solutions offered
17.1.18 EUROFINS SCIENTIFIC
17.1.18.1 Business overview
17.1.18.2 Products/Services/Solutions offered
17.1.18.3 Recent developments
17.1.18.3.1 Service launches
17.1.18.3.2 Expansions
17.1.19 BIO-RAD LABORATORIES, INC.
17.1.19.1 Business overview
17.1.19.2 Products/Services/Solutions offered
17.1.19.3 Recent developments
17.1.19.3.1 Product launches
17.1.19.3.2 Deals
17.1.20 QIAGEN
17.1.20.1 Business overview
17.1.20.2 Products/Services/Solutions offered
17.1.20.3 Recent developments
17.1.20.3.1 Product launches
17.2 OTHER PLAYERS
17.2.1 PROMEGA CORPORATION
17.2.2 CATALENT, INC.
17.2.3 ASSOCIATES OF CAPE COD, INC.
17.2.4 CLEAN BIOLOGICS
17.2.5 PATHOQUEST
17.2.6 PACIFIC BIOLABS
17.2.7 ARL BIO PHARMA, INC.
17.2.8 FRONTAGE LABS
17.2.9 CREATIVE BIOGENE
17.2.10 ADVAXIA BIOLOGICS
18 RESEARCH METHODOLOGY
18.1 RESEARCH DATA
18.1.1 SECONDARY DATA
18.1.2 PRIMARY DATA
18.2 MARKET ESTIMATION METHODOLOGY
18.2.1 MARKET SIZE ESTIMATION
18.2.2 INSIGHTS OF PRIMARY EXPERTS
18.2.3 TOP-DOWN APPROACH
18.3 MARKET GROWTH RATE PROJECTIONS
18.4 MARKET BREAKDOWN AND DATA TRIANGULATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.7 RISK ANALYSIS
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS
19.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 BIOLOGICS SAFETY TESTING MARKET: IMPACT ANALYSIS
TABLE 2 BIOLOGICS SAFETY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 BIOLOGICS SAFETY TESTING MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 5 INDICATIVE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2025
TABLE 6 BIOLOGICS SAFETY TESTING MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 7 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 8 APPLICATIONS OF PCR IN BIOLOGICS SAFETY TESTING
TABLE 9 INDICATIVE LIST OF PATENTS IN BIOLOGICS SAFETY TESTING MARKET, 2025
TABLE 10 CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET
TABLE 11 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 COUNTRY-WISE REGULATORY SCENARIO FOR BIOLOGICS SAFETY TESTING MANUFACTURERS
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
TABLE 18 KEY BUYING CRITERIA, BY END USER
TABLE 19 BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 20 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 21 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 22 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 23 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 24 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 27 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28 VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 NORTH AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 EUROPE: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 ASIA PACIFIC: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 LATIN AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 MIDDLE EAST: VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 GCC COUNTRIES: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 STERILITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 NORTH AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 EUROPE: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASIA PACIFIC: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 LATIN AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 MIDDLE EAST: STERILITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 GCC COUNTRIES: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 MIDDLE EAST: MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 GCC COUNTRIES: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 NORTH AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 EUROPE: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 ASIA PACIFIC: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 LATIN AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 MIDDLE EAST: ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 GCC COUNTRIES: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 EUROPE: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 ASIA PACIFIC: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 LATIN AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 MIDDLE EAST: BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 GCC COUNTRIES: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 OTHER BST SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 NORTH AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 EUROPE: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 ASIA PACIFIC: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 LATIN AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 MIDDLE EAST: OTHER BST SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 GCC COUNTRIES: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 71 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 79 BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 MIDDLE EAST: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 GCC COUNTRIES: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 DETECTION KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 LATIN AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 MIDDLE EAST: DETECTION KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 GCC COUNTRIES: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 EUROPE: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 LATIN AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 MIDDLE EAST: ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 GCC COUNTRIES: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 MIDDLE EAST: STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 GCC COUNTRIES: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 BIOBURDEN ENUMERATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 LATIN AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 MIDDLE EAST: BIOBURDEN ENUMERATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 GCC COUNTRIES: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 NORTH AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 EUROPE: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 LATIN AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 MIDDLE EAST: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 GCC COUNTRIES: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 130 NORTH AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 EUROPE: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 ASIA PACIFIC: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 LATIN AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 MIDDLE EAST: DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 135 GCC COUNTRIES: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 137 NORTH AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 EUROPE: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 ASIA PACIFIC: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 LATIN AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 MIDDLE EAST: SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 GCC COUNTRIES: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 MIDDLE EAST: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 GCC COUNTRIES: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 OTHER BST INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 LATIN AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 MIDDLE EAST: OTHER BST INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 156 GCC COUNTRIES: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 158 VIRUS SAFETY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 LATIN AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 MIDDLE EAST: VIRUS SAFETY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 GCC COUNTRIES: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 STERILITY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 LATIN AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MIDDLE EAST: STERILITY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 ENDOTOXIN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 LATIN AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 MIDDLE EAST: ENDOTOXIN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 GCC COUNTRIES: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 MYCOPLASMA TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 MIDDLE EAST: MYCOPLASMA TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 GCC COUNTRIES: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 BIOBURDEN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 LATIN AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 MIDDLE EAST: BIOBURDEN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 GCC COUNTRIES: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 LATIN AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 MIDDLE EAST: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 199 GCC COUNTRIES: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 OTHER TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 EUROPE: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 MIDDLE EAST: OTHER TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 GCC COUNTRIES: OTHER BST TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 208 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 223 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 228 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 230 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 235 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 237 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 242 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 244 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 252 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 257 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 259 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 266 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 271 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 273 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 278 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 280 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 286 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 288 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 289 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 293 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 295 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 296 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 300 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 302 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 303 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 1 BIOLOGICS SAFETY TESTING MARKET: IMPACT ANALYSIS
TABLE 2 BIOLOGICS SAFETY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 BIOLOGICS SAFETY TESTING MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 5 INDICATIVE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2025
TABLE 6 BIOLOGICS SAFETY TESTING MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 7 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 8 APPLICATIONS OF PCR IN BIOLOGICS SAFETY TESTING
TABLE 9 INDICATIVE LIST OF PATENTS IN BIOLOGICS SAFETY TESTING MARKET, 2025
TABLE 10 CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET
TABLE 11 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 COUNTRY-WISE REGULATORY SCENARIO FOR BIOLOGICS SAFETY TESTING MANUFACTURERS
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
TABLE 18 KEY BUYING CRITERIA, BY END USER
TABLE 19 BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 20 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 21 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 22 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 23 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 24 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 27 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28 VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 NORTH AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 EUROPE: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 ASIA PACIFIC: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 LATIN AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 MIDDLE EAST: VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 GCC COUNTRIES: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 STERILITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 NORTH AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 EUROPE: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASIA PACIFIC: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 LATIN AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 MIDDLE EAST: STERILITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 GCC COUNTRIES: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 MIDDLE EAST: MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 GCC COUNTRIES: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 NORTH AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 EUROPE: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 ASIA PACIFIC: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 LATIN AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 MIDDLE EAST: ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 GCC COUNTRIES: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 EUROPE: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 ASIA PACIFIC: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 LATIN AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 MIDDLE EAST: BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 GCC COUNTRIES: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 OTHER BST SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 NORTH AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 EUROPE: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 ASIA PACIFIC: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 LATIN AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 MIDDLE EAST: OTHER BST SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 GCC COUNTRIES: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 71 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 79 BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 MIDDLE EAST: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 GCC COUNTRIES: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 DETECTION KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 LATIN AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 MIDDLE EAST: DETECTION KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 GCC COUNTRIES: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 EUROPE: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 LATIN AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 MIDDLE EAST: ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 GCC COUNTRIES: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 MIDDLE EAST: STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 GCC COUNTRIES: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 BIOBURDEN ENUMERATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 LATIN AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 MIDDLE EAST: BIOBURDEN ENUMERATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 GCC COUNTRIES: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 NORTH AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 EUROPE: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 LATIN AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 MIDDLE EAST: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 GCC COUNTRIES: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 130 NORTH AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 EUROPE: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 ASIA PACIFIC: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 LATIN AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 MIDDLE EAST: DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 135 GCC COUNTRIES: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 137 NORTH AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 EUROPE: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 ASIA PACIFIC: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 LATIN AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 MIDDLE EAST: SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 GCC COUNTRIES: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 MIDDLE EAST: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 GCC COUNTRIES: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 OTHER BST INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 LATIN AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 MIDDLE EAST: OTHER BST INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 156 GCC COUNTRIES: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 158 VIRUS SAFETY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 LATIN AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 MIDDLE EAST: VIRUS SAFETY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 GCC COUNTRIES: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 STERILITY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 LATIN AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MIDDLE EAST: STERILITY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 ENDOTOXIN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 LATIN AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 MIDDLE EAST: ENDOTOXIN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 GCC COUNTRIES: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 MYCOPLASMA TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 MIDDLE EAST: MYCOPLASMA TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 GCC COUNTRIES: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 BIOBURDEN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 LATIN AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 MIDDLE EAST: BIOBURDEN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 GCC COUNTRIES: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 LATIN AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 MIDDLE EAST: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 199 GCC COUNTRIES: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 OTHER TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 EUROPE: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 MIDDLE EAST: OTHER TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 GCC COUNTRIES: OTHER BST TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 208 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 223 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 228 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 230 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 235 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 237 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 242 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 244 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 252 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 257 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 259 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 266 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 271 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 273 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 278 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 280 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 286 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 288 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 289 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 293 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 295 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 296 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 300 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 302 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 303 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL BIOLOGICS SAFETY TESTING MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOLOGICS SAFETY TESTING MARKET, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF BIOLOGICS SAFETY TESTING MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN BIOLOGICS SAFETY TESTING MARKET, 2026–2031
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOLOGICS SAFETY TESTING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 7 GROWING BIOLOGICS AND BIOSIMILARS PIPELINE TO DRIVE GROWTH IN BIOLOGICS SAFETY TESTING MARKET
FIGURE 8 SERVICES SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE, BY OFFERING, IN 2025
FIGURE 9 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10 BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 BIOLOGICS SAFETY TESTING MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 12 BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS
FIGURE 13 BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS
FIGURE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
FIGURE 15 INDICATIVE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2025
FIGURE 16 BIOLOGICS SAFETY TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 17 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 18 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015–2025
FIGURE 19 IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 21 KEY BUYING CRITERIA, BY END USER
FIGURE 22 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 26 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 27 BIOLOGICS SAFETY TESTING MARKET: COMPANY FOOTPRINT
FIGURE 28 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 29 EV/EBITDA OF KEY VENDORS
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 31 BIOLOGICS SAFETY TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 32 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 33 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025)
FIGURE 34 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2025)
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 38 LONZA: COMPANY SNAPSHOT (2025)
FIGURE 39 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 40 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
FIGURE 42 WUXI APPTEC: COMPANY SNAPSHOT
FIGURE 43 SGS SOCI?T? G?N?RALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2025)
FIGURE 44 SOTERA HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 45 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2025)
FIGURE 46 GENSCRIPT: COMPANY SNAPSHOT (2025)
FIGURE 47 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 49 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 50 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 52 RESEARCH DESIGN
FIGURE 53 BIOLOGICS SAFETY TESTING MARKET: BREAKDOWN OF PRIMARIES
FIGURE 54 BIOLOGICS SAFETY TESTING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 55 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 56 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2025)
FIGURE 57 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 58 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 59 BIOLOGICS SAFETY TESTING MARKET CAGR PROJECTIONS
FIGURE 60 DATA TRIANGULATION METHODOLOGY
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL BIOLOGICS SAFETY TESTING MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOLOGICS SAFETY TESTING MARKET, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF BIOLOGICS SAFETY TESTING MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN BIOLOGICS SAFETY TESTING MARKET, 2026–2031
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOLOGICS SAFETY TESTING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 7 GROWING BIOLOGICS AND BIOSIMILARS PIPELINE TO DRIVE GROWTH IN BIOLOGICS SAFETY TESTING MARKET
FIGURE 8 SERVICES SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE, BY OFFERING, IN 2025
FIGURE 9 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10 BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 BIOLOGICS SAFETY TESTING MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 12 BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS
FIGURE 13 BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS
FIGURE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
FIGURE 15 INDICATIVE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2025
FIGURE 16 BIOLOGICS SAFETY TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 17 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 18 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015–2025
FIGURE 19 IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 21 KEY BUYING CRITERIA, BY END USER
FIGURE 22 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 26 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 27 BIOLOGICS SAFETY TESTING MARKET: COMPANY FOOTPRINT
FIGURE 28 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 29 EV/EBITDA OF KEY VENDORS
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 31 BIOLOGICS SAFETY TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 32 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 33 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025)
FIGURE 34 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2025)
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 38 LONZA: COMPANY SNAPSHOT (2025)
FIGURE 39 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 40 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
FIGURE 42 WUXI APPTEC: COMPANY SNAPSHOT
FIGURE 43 SGS SOCI?T? G?N?RALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2025)
FIGURE 44 SOTERA HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 45 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2025)
FIGURE 46 GENSCRIPT: COMPANY SNAPSHOT (2025)
FIGURE 47 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 49 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 50 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 52 RESEARCH DESIGN
FIGURE 53 BIOLOGICS SAFETY TESTING MARKET: BREAKDOWN OF PRIMARIES
FIGURE 54 BIOLOGICS SAFETY TESTING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 55 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 56 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2025)
FIGURE 57 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 58 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 59 BIOLOGICS SAFETY TESTING MARKET CAGR PROJECTIONS
FIGURE 60 DATA TRIANGULATION METHODOLOGY
